CLINICAL NUCLEAR MEDICINE, cilt.40, sa.10, ss.799-801, 2015 (SCI-Expanded)
Peptide receptor radionuclide therapy with Lu-177 or Y-90 is promising with successful results in somatostatin receptor-positive tumors. In all radiation therapies, knowledge of the radiation dose received by the target, and other organs in the body is essential to evaluate the risks and benefits of any procedure. We report a case of liver metastases from a rectal neuroendocrine tumor, which was treated with Y-90 DOTANOC. Posttreatment whole-body planar images were acquired through Bremsstrahlung radiations of Y-90 on a gamma-camera, and thoracolumbar PET/CT images were acquired on PET.